Acura Pharmaceuticals Net Change in Short-term Investments 2010-2021 | ACUR

Acura Pharmaceuticals net change in short-term investments from 2010 to 2021. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
Acura Pharmaceuticals Annual Net Change in Short-term Investments
(Millions of US $)
2021 $N/A
2020 $N/A
2019 $N/A
2018 $N/A
2017 $N/A
2016 $11
2015 $0
2014 $2
2013 $6
2012 $-20
2011 $N/A
2010 $N/A
2009 $5
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.001B $0.000B
Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.207B 6.94
Dr Reddy's Laboratories (RDY) India $12.054B 21.88
BridgeBio Pharma (BBIO) United States $6.426B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.872B 15.20
Bausch Health Cos (BHC) Canada $1.692B 1.25
Amphastar Pharmaceuticals (AMPH) United States $1.181B 7.87
Taysha Gene Therapies (TSHA) United States $0.554B 0.00
Personalis (PSNL) United States $0.437B 0.00
Assembly Biosciences (ASMB) United States $0.103B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00